Anika Reports Fourth Quarter and Year-End 2023 Financial Results
BEDFORD, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today reported financial results for its fourth quarter and full year ended December 31, 2023.
- Revenue in the fourth quarter of 2023 was $43.0 million, up 8% compared to $39.6 million in the fourth quarter of 2022.
- Adjusted EBITDA1 was $5.8 million, compared to $1.4 million in the fourth quarter of 2022.
- “We are pleased to report strong fourth quarter and full year results, including a record year in OA Pain Management.
- In 2023, Anika launched multiple meaningful new products and made considerable progress addressing the new MDR regulatory requirements in Europe.